PEGASYS 180 MCG / 0.5 ML — DIN 02248077
PEGINTERFERON ALFA-2A : 180 MCG / 0.5 ML · PHARMAAND GMBH · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is PEGASYS?
PEGASYS 180 MCG / 0.5 ML contains PEGINTERFERON ALFA-2A : 180 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02248077, held by PHARMAAND GMBH, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 03-Jun-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PEGASYS used for?
PEGASYS (peginterferon alfa-2a) is indicated for the treatment of Chronic Hepatitis C in: • Adult patients without cirrhosis • Adult patients with compensated cirrhosis, including HCV/HIV co-infection patients with stable HIV disease with or without antiretroviral therapy. PEGASYS is indicated for the treatment of both HBeAg-positive and HBeAg-negative chronic hepatitis B in: • Patients with compensated liver disease, liver inflammation and evidence of viral replication (both cirrhotic and non-cirrhotic disease).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Peginterferon Alfa-2a cost around the world?
Peginterferon Alfa-2a is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 2 | 12 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 3 | CZK███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 2 | NOK███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
27 pack listings across 14 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Peginterferon Alfa-2a pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Peginterferon Alfa-2a in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Peginterferon Alfa-2a, across 2 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMAAND GMBH | 1 | 1 | PEGASYS | Sourceable in Canada |
| HOFFMANN-LA ROCHE LIMITED | 1 | 0 | PEGASYS | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 180 MCG / 0.5 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | Pre-filled syringes: 180 mcg/0.5 mL; Single-use Vials: 180 mcg/1 mL; ProClick® Autoinjector: 180 mcg/0.5 mL |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Peginterferon Alfa-2a |
|---|---|
| ATC code | L03AB11 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02248077 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2248077 |
| Brand name | PEGASYS |
| Generic / active ingredient | PEGINTERFERON ALFA-2A : 180 MCG / 0.5 ML |
| Market authorization holder | PHARMAAND GMBH |
| Health Canada schedule | Prescription |
| ATC code | L03AB11 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L03AB |
| Current status | MARKETED |
| Status date | 03-Jun-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PEGASYS | 180 MCG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | 02248078 |
2 · Same class — other molecules in ATC L03AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Interferon Beta-1a | AVONEX · REBIF | 11 | 5 | Yes |
| Peginterferon Beta-1a | PLEGRIDY | 4 | 2 | Yes |
| Interferon Beta-1b | BETASERON · EXTAVIA | 2 | 1 | Yes |
| Peginterferon Alfa-2a | PEGASYS | 2 | 1 | Yes |
| Peginterferon Alfa-2b, Combinations | PEGETRON · REBETRON READY TO USE SOLUTION (ALBUMIN(HUMAN)FREE) (6000000 IU/ML AND 200MG CAPSULES) · REBETRON SOLUTION (ALBUMIN (HUMAN) FREE) (18 MIU MULTI-DOSE PEN / 200MG CAPSULES) · VICTRELIS TRIPLE | 15 | 0 | Not in Canada |
| Interferon Alfa-2b | INTRON A · INTRON A - KIT (PWS+DILUENT) 3000000IU/VIAL · INTRON A - KIT (PWS+DILUENT) 5000000IU/VIAL · INTRON A - LIQ 5000000IU/ML · +3 more | 13 | 0 | Not in Canada |
| Interferon Alfa-2a | ROFERON A SOLN INJ 6 MILLION · ROFERON A STERILE PWS 18M UNIT/VIAL · ROFERON A STERILE PWS 3M UNIT/VIAL · ROFERON A STERILE PWS 9M UNIT/VIAL · +8 more | 12 | 0 | Not in Canada |
| Peginterferon Alfa-2b | UNITRON PEG | 4 | 0 | Not in Canada |
| Peginterferon Alfa-2a, Combinations | PEGASYS RBV | 2 | 0 | Not in Canada |
| Interferon Alfa-N1 | WELLFERON INJ 10 000 000UNIT/ML · WELLFERON INJ 3000000UNIT/ML | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L03AA | Ancestim · Filgrastim · Pegfilgrastim | 24 | 21 |
| L03AX | Bcg Vaccine · Glatiramer Acetate · Melanoma Vaccine · Plerixafor | 18 | 8 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PEGASYS called?
The same molecule, Peginterferon Alfa-2a, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Pegasys (Ireland) | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.